IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the company focused on delivering imaging platforms to treat patients more effectively, enjoyed a boost on the London market this Tuesday, with shares being sent 4% higher.
Investors were buoyed by positive outcomes of two recent pre-clinical studies pertaining to the inhibitory effects of oral gallium maltolate (GaM) on two types of pediatric brain tumours.
The oral GaM investigated in these studies is the same agent currently being assessed in a phase-I clinical trial for adult GBM, sponsored by IQ-AI.
IQ-AI shares were changing hands for 2.8p, with a market capitalisation of £5.1mln as of 10.50am.